Advances in targeted therapy of cholangiocarcinoma

References

• Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):1. doi: 10.1038/s41572-021-00300-2.
   PubMed Web of Science ®Google Scholar
• Cardinale V. Classifications and misclassification in cholangiocarcinoma. Liver Int. 2019;39(2):260–12. doi: 10.1111/liv.13998.
   PubMed Web of Science ®Google Scholar
• Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737. doi: 10.1016/j.aohep.2022.100737.
   PubMed Web of Science ®Google Scholar
• Chen C, Jiang J, Fang M, et al. MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma. J Cancer. 2020;11(11):3216–3224. doi: 10.7150/jca.41492.
   PubMed Web of Science ®Google Scholar
• Liu S, Liu X, Li X, et al. Application of laparoscopic radical resection for type III and IV hilar cholangiocarcinoma treatment. Gastroenterol Res Pract. 2020;2020:1506275–1506276. doi: 10.1155/2020/1506275.
   PubMed Web of Science ®Google Scholar
• Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315–327. doi: 10.1016/j.jhep.2020.03.008.
   PubMed Web of Science ®Google Scholar
• Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95–103. doi: 10.1016/j.jhep.2019.09.007.
   PubMed Web of Science ®Google Scholar
• Sripa B, Tangkawattana S, Brindley PJ. Update on pathogenesis of opisthorchiasis and cholangiocarcinoma. Adv Parasitol. 2018;102:97–113. doi: 10.1016/bs.apar.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1(S1):98–107. doi: 10.1111/liv.14086.
   PubMedGoogle Scholar
• Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–140. doi: 10.1016/j.annonc.2022.10.506.
   PubMed Web of Science ®Google Scholar
• Li Y, Song Y, Liu S. The new insight of treatment in cholangiocarcinoma. J Cancer. 2022;13(2):450–464. doi: 10.7150/jca.68264.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi: 10.1038/ng.3375.
   PubMed Web of Science ®Google Scholar
• Macias RIR, Rimassa L, Lamarca A. The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment. Hepatobiliary Surg Nutr. 2023;12(3):457–461. doi: 10.21037/hbsn-23-215.
   PubMed Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962. doi: 10.1158/2159-8290.CD-17-0245.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi: 10.1056/NEJMoa0908721.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. doi: 10.1016/s1470-2045(21)00027-9.
   PubMed Web of Science ®Google Scholar
• Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol. 2017;90(1076):20170061. doi: 10.1259/bjr.20170061.
   PubMed Web of Science ®Google Scholar
• Luvira V, Satitkarnmanee E, Pugkhem A, et al. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev. 2021;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Wahida A, Buschhorn L, Fröhling S, et al. The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2023;23(1):43–54. doi: 10.1038/s41568-022-00529-3.
   PubMed Web of Science ®Google Scholar
• Capuozzo M, Santorsola M, Landi L, et al. Evolution of treatment in advanced cholangiocarcinoma: old and new towards precision oncology. Int J Mol Sci. 2022;23(23):15124. doi: 10.3390/ijms232315124.
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31(2):178–186. doi: 10.1038/s41422-020-0375-9.
   PubMed Web of Science ®Google Scholar
• Yu Y, Chen K, Fan Y. Extensive-stage small-cell lung cancer: current management and future directions. Int J Cancer. 2023;152(11):2243–2256. doi: 10.1002/ijc.34346.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi: 10.1038/s41571-018-0073-4.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–242. doi: 10.1634/theoncologist.2013-0352.
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. doi: 10.1002/cncr.30254.
   PubMed Web of Science ®Google Scholar
• Massironi S, Pilla L, Elvevi A, et al. New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells. 2020;9(3):688. doi: 10.3390/cells9030688.
   PubMed Web of Science ®Google Scholar
• Wagner JP, Wolf-Yadlin A, Sevecka M, et al. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal. 2013;6(284):ra58. doi: 10.1126/scisignal.2003994.
   PubMed Web of Science ®Google Scholar
• Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16(2):105–122. doi: 10.1038/s41571-018-0115-y.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–266. doi: 10.1002/wdev.176.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. doi: 10.1200/JCO.2017.75.5009.
   PubMed Web of Science ®Google Scholar
• Salati M, Caputo F, Baldessari C, et al. The evolving role of FGFR2 inhibitors in intrahepatic cholangiocarcinoma: from molecular biology to clinical targeting. Cancer Manag Res. 2021;13:7747–7757. doi: 10.2147/CMAR.S330710.
   PubMed Web of Science ®Google Scholar
• Yang R, Song Y, Shakoor K, et al. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma. Mol Med Rep. 2022;25(5):171. doi: 10.3892/mmr.2022.12687.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. doi: 10.1016/s1470-2045(20)30109-1.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Lian BF, Dong QZ, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim Biophys Acta Mol Basis Dis. 2018;1864(6 Pt B):2360–2368. doi: 10.1016/j.bbadis.2018.01.027.
   PubMed Web of Science ®Google Scholar
• Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803–815. doi: 10.1016/s2468-1253(21)00196-5.
   PubMed Web of Science ®Google Scholar
• Krook MA, Lenyo A, Wilberding M, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19(3):847–857. doi: 10.1158/1535-7163.MCT-19-0631.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079. doi: 10.1158/2159-8290.CD-19-0182.
   PubMed Web of Science ®Google Scholar
• Javle MM, Shaib WL, Braun S, et al. FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/a). J Clin Oncol. 2020;38(4_suppl):TPS597–TPS597. doi: 10.1200/JCO.2020.38.4_suppl.TPS597.
   Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24(1):677–736. doi: 10.1146/annurev.neuro.24.1.677.
   PubMed Web of Science ®Google Scholar
• Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24(23):5807–5814. doi: 10.1158/1078-0432.CCR-18-1156.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi: 10.1056/NEJMoa1714448.
   PubMed Web of Science ®Google Scholar
• Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30 Suppl 8:viii23–viii30. doi: 10.1093/annonc/mdz282.
   PubMedGoogle Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409. doi: 10.1158/2159-8290.CD-16-1237.
   PubMed Web of Science ®Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A Next-Generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–972. doi: 10.1158/2159-8290.CD-17-0507.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang H-M, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188. doi: 10.1016/s1470-2045(11)70301-1.
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–828. doi: 10.1016/s1470-2045(14)70212-8.
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–1148. doi: 10.1016/s1470-2045(10)70247-3.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Mykulowycz K, Uehara T, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24(12):3061–3065. doi: 10.1093/annonc/mdt416.
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811–816. doi: 10.1038/nature04433.
   PubMed Web of Science ®Google Scholar
• Dang L, Su SM. Isocitrate dehydrogenase mutation and (R)-2-Hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem. 2017;86(1):305–331. doi: 10.1146/annurev-biochem-061516-044732.
   PubMed Web of Science ®Google Scholar
• Yang H, Ye D, Guan KL, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–5571. doi: 10.1158/1078-0432.CCR-12-1773.
   PubMed Web of Science ®Google Scholar
• Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10(6):507–520. doi: 10.1177/1756283X17698090.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017;67(3):632–644. doi: 10.1016/j.jhep.2017.03.026.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi: 10.1016/s1470-2045(20)30157-1.
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417. doi: 10.3389/fonc.2019.00417.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736. doi: 10.1056/NEJMoa1502309.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–1316. doi: 10.1016/s1470-2045(17)30679-4.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–1473. doi: 10.1038/ng.2813.
   PubMed Web of Science ®Google Scholar
• Fouassier L, Marzioni M, Afonso MB, et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39 Suppl 1(S1):43–62. doi: 10.1111/liv.14102.
   PubMedGoogle Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54. doi: 10.1016/S1470-2045(09)70333-X.
   PubMed Web of Science ®Google Scholar
• Iyer RV, Pokuri VK, Groman A, et al. A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol. 2018;41(7):649–655. doi: 10.1097/COC.0000000000000347.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sanoff HK, Poklepovic AS, et al. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020;126(15):3464–3470. doi: 10.1002/cncr.32964.
   PubMed Web of Science ®Google Scholar
• Sun W, Patel A, Normolle D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125(6):902–909. doi: 10.1002/cncr.31872.
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-Centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522–532. doi: 10.1016/S2468-1253(22)00043-7.
   PubMed Web of Science ®Google Scholar
• Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013;73(2):897–907. doi: 10.1158/0008-5472.CAN-12-2130.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Brivio S, Mertens J, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019;70(4):700–709. doi: 10.1016/j.jhep.2018.12.004.
   PubMed Web of Science ®Google Scholar
• Sirica AE. Matricellular proteins in intrahepatic cholangiocarcinoma. Adv Cancer Res. 2022;156:249–281. doi: 10.1016/bs.acr.2022.01.010.
   PubMedGoogle Scholar
• Fabris L, Cadamuro M, Cagnin S, et al. Liver matrix in benign and malignant biliary tract disease. Semin Liver Dis. 2020;40(3):282–297. doi: 10.1055/s-0040-1705109.
   PubMed Web of Science ®Google Scholar
• Carpino G, Overi D, Melandro F, et al. Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin Proteomics. 2019;16(1):37. doi: 10.1186/s12014-019-9257-x.
   PubMed Web of Science ®Google Scholar
• Yoo SY, Badrinath N, Lee HL, et al. A cancer-favoring, engineered vaccinia virus for cholangiocarcinoma. Cancers (Basel). 2019;11(11):1667. doi: 10.3390/cancers11111667.
   PubMed Web of Science ®Google Scholar
• Taylor MH, Schmidt EV, Dutcus C, et al. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021;17(6):637–648. doi: 10.2217/fon-2020-0937.
   PubMed Web of Science ®Google Scholar
• Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414–424. doi: 10.21037/hbsn-20-338.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Cope L, Ruggieri AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24):e152670. doi: 10.1172/JCI152670.
   PubMed Web of Science ®Google Scholar